<?xml version="1.0" encoding="UTF-8"?>
<p id="Par17">Lopinavir was first approved in the United States in 2000 for the treatment of HIV infection [
 <xref ref-type="bibr" rid="CR20">20</xref>]. It is a protease inhibitor and is usually used in combination with ritonavir to increase its half-life through the inhibition of cytochrome P450 [
 <xref ref-type="bibr" rid="CR21">21</xref>]. In vitro studies have shown that lopinavir/ritonavir can inhibit the replication of MERS-CoV and SARS-CoV and exert antiviral effects [
 <xref ref-type="bibr" rid="CR22">22</xref>–
 <xref ref-type="bibr" rid="CR25">25</xref>]. At present, the drug has been used in the clinical treatment of COVID-19 at a dose of 400 mg/100 mg for adults twice daily, and the course of treatment does not exceed 10 days [
 <xref ref-type="bibr" rid="CR13">13</xref>]. However, this treatment has certain toxic and side effects on the treatment of COVID-19. Therefore, its safety and effectiveness require further research. Recently, some clinical studies have shown that lopinavir/ritonavir treatment has no significant effect [
 <xref ref-type="bibr" rid="CR26">26</xref>, 
 <xref ref-type="bibr" rid="CR27">27</xref>].
</p>
